Few differences observed in safety information for biosimilars and related originators
A cross-sectional analysis of the safety concerns of biosimilars, compared with their originator products, shows very similar results.
Biosimilars have been available in the European Union for more than ten years, but their uptake in routine care across the region is highly variable.
A cross-sectional analysis was conducted on publicly available information on biosimilars and their originators, filed for regulatory purposes at European Medicines Agency level. A total of 19 biosimilars and 6 originators were included.
Overall, 142 safety concerns were retrieved, corresponding to 55 general safety concerns. Of these, 22(40%) were classified as highly clinically relevant, with 21(38%) as medium and 12(22%) as low clinical relevance.
For all substances, except infliximab, no, or only one, difference was found in the safety concerns reported for biosimilars and their originators. For infliximab, a single difference was considered a highly clinically relevant safety issue.
Direct comparison between biosimilars and related originators through formal post-marketing studies remains important to evaluate specific safety and effectiveness issues, the researchers concluded in the British Journal of Clinical Pharmacology (online, 22 November 2017).
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204187
Recommended from Pharmaceutical Press
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£138.50
Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£262.50
Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.£22.00
An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.£33.00